MX2022006807A - Análogos de rapamicina y usos de estos. - Google Patents
Análogos de rapamicina y usos de estos.Info
- Publication number
- MX2022006807A MX2022006807A MX2022006807A MX2022006807A MX2022006807A MX 2022006807 A MX2022006807 A MX 2022006807A MX 2022006807 A MX2022006807 A MX 2022006807A MX 2022006807 A MX2022006807 A MX 2022006807A MX 2022006807 A MX2022006807 A MX 2022006807A
- Authority
- MX
- Mexico
- Prior art keywords
- present
- compositions
- methods
- compounds
- rapamycin analogs
- Prior art date
Links
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 102000008135 Mechanistic Target of Rapamycin Complex 1 Human genes 0.000 abstract 1
- 108010035196 Mechanistic Target of Rapamycin Complex 1 Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962944166P | 2019-12-05 | 2019-12-05 | |
| PCT/US2020/063351 WO2021113665A1 (en) | 2019-12-05 | 2020-12-04 | Rapamycin analogs and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022006807A true MX2022006807A (es) | 2022-09-12 |
Family
ID=76222025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022006807A MX2022006807A (es) | 2019-12-05 | 2020-12-04 | Análogos de rapamicina y usos de estos. |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11819476B2 (https=) |
| EP (1) | EP4069223A4 (https=) |
| JP (1) | JP2023506410A (https=) |
| KR (1) | KR20220128345A (https=) |
| CN (1) | CN115209897A (https=) |
| AU (1) | AU2020397938A1 (https=) |
| BR (1) | BR112022010754A2 (https=) |
| CA (1) | CA3163680A1 (https=) |
| IL (1) | IL293549A (https=) |
| MX (1) | MX2022006807A (https=) |
| TW (1) | TW202134234A (https=) |
| WO (1) | WO2021113665A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3914245A4 (en) | 2019-01-22 | 2022-08-24 | Aeovian Pharmaceuticals, Inc. | MTORC-1 MODULATORS AND USES THEREOF |
| KR20220128345A (ko) * | 2019-12-05 | 2022-09-20 | 아나쿠리아 테라퓨틱스, 인코포레이티드 | 라파마이신 유사체 및 이의 용도 |
| WO2021195599A1 (en) * | 2020-03-27 | 2021-09-30 | Aeovian Pharmaceuticals, Inc. | Mtorc1 modulators and uses thereof |
| EP4185590A2 (en) * | 2020-07-21 | 2023-05-31 | Aeovian Pharmaceuticals, Inc. | Mtorc1 modulators and uses thereof |
| CN116917294A (zh) * | 2021-01-22 | 2023-10-20 | 詹森药业有限公司 | 雷帕霉素类似物及其用途 |
| JP2024503898A (ja) * | 2021-01-22 | 2024-01-29 | ヤンセン ファーマシューティカ エヌ．ベー． | ラパマイシン類似体及びその使用 |
| CN114539203A (zh) * | 2022-03-10 | 2022-05-27 | 李科 | 一种低成本碳酸亚乙烯酯的合成方法 |
| WO2023196676A1 (en) * | 2022-04-09 | 2023-10-12 | The Brigham And Women's Hospital, Inc. | Treating tuberous sclerosis complex-associated diseases |
| CN115097046B (zh) * | 2022-07-07 | 2023-09-26 | 国药集团川抗制药有限公司 | 一种分离雷帕霉素及其杂质的方法 |
| CN116642992A (zh) * | 2023-04-27 | 2023-08-25 | 河北省药品医疗器械检验研究院(河北省化妆品检验研究中心) | 一种人体血浆抗肝癌哺乳动物雷帕霉素靶蛋白抑制剂串联质谱检测试剂盒 |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA935112B (en) | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
| US5260300A (en) | 1992-11-19 | 1993-11-09 | American Home Products Corporation | Rapamycin carbonate esters as immuno-suppressant agents |
| WO1994025072A1 (en) | 1993-04-23 | 1994-11-10 | American Home Products Corporation | Rapamycin conjugates and antibodies |
| WO1995014023A1 (en) * | 1993-11-19 | 1995-05-26 | Abbott Laboratories | Semisynthetic analogs of rapamycin (macrolides) being immunomodulators |
| US5912253A (en) | 1993-12-17 | 1999-06-15 | Novartis Ag | Rapamycin derivatives |
| US5362735A (en) | 1994-02-23 | 1994-11-08 | Smithkline Beecham Corporation | Rapamycin derivatives |
| US5639600A (en) | 1994-08-05 | 1997-06-17 | The Regents Of The University Of California | Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement |
| JP3934705B2 (ja) * | 1995-05-26 | 2007-06-20 | ノバルティス ファーマ株式会社 | サイクロデキストリン組成物 |
| KR19990022651A (ko) | 1995-06-07 | 1999-03-25 | 데이비드 엘. 버스테인 | 생물학적 사건에 대한 라파마이신 기재 조절방법 |
| EP0833828B1 (en) | 1995-06-09 | 2002-11-20 | Novartis AG | Rapamycin derivatives |
| US6258823B1 (en) * | 1996-07-12 | 2001-07-10 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
| JP2002514165A (ja) * | 1996-07-12 | 2002-05-14 | アリアド・ファーマシューティカルズ・インコーポレイテッド | 病原性真菌感染の治療または予防材料および方法 |
| US5922730A (en) | 1996-09-09 | 1999-07-13 | American Home Products Corporation | Alkylated rapamycin derivatives |
| CN1235608A (zh) | 1996-09-09 | 1999-11-17 | 美国家用产品公司 | 烷基化的雷帕霉素衍生物 |
| US6342507B1 (en) | 1997-09-05 | 2002-01-29 | Isotechnika, Inc. | Deuterated rapamycin compounds, method and uses thereof |
| US7087648B1 (en) | 1997-10-27 | 2006-08-08 | The Regents Of The University Of California | Methods for modulating macrophage proliferation using polyamine analogs |
| CA2318402A1 (en) * | 1998-01-15 | 1999-07-22 | Ariad Gene Therapeutics, Inc. | Regulation of biological events using multimeric chimeric proteins |
| AU783158B2 (en) * | 1999-08-24 | 2005-09-29 | Ariad Pharmaceuticals, Inc. | 28-epirapalogs |
| US7067526B1 (en) | 1999-08-24 | 2006-06-27 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
| TWI256395B (en) | 1999-09-29 | 2006-06-11 | Wyeth Corp | Regioselective synthesis of rapamycin derivatives |
| EP1382339B1 (en) | 1999-12-10 | 2007-12-05 | Pfizer Products Inc. | Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| EP1389617B1 (en) | 2001-04-27 | 2007-01-03 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compound and antitumor agent containing the same as active ingredient |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| US20040001878A1 (en) * | 2002-06-26 | 2004-01-01 | Deroyal Industries, Inc. | Infused wound care dressings |
| WO2004019973A1 (en) | 2002-08-14 | 2004-03-11 | Atugen Ag | Use of protein kinase n beta |
| KR20070087266A (ko) | 2003-04-03 | 2007-08-28 | 세마포르 파머슈티컬즈, 아이엔씨. | 피아이-3 키나아제 억제제 프로드러그 |
| CN1832939B (zh) | 2003-05-30 | 2010-04-28 | 杰明X医药品加拿大公司 | 用于治疗癌症或病毒病的三杂环化合物、组合物和方法 |
| US7173015B2 (en) | 2003-07-03 | 2007-02-06 | The Trustees Of The University Of Pennsylvania | Inhibition of Syk kinase expression |
| AU2004255340B2 (en) * | 2003-07-08 | 2008-05-01 | Novartis Ag | Use of rapamycin and rapamycin derivatives for the treatment of bone loss |
| US7220755B2 (en) | 2003-11-12 | 2007-05-22 | Biosensors International Group, Ltd. | 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same |
| SI2612862T1 (sl) | 2004-05-13 | 2017-04-26 | Icos Corporation | Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta |
| US20060189551A1 (en) * | 2004-10-04 | 2006-08-24 | Duke University | Combination therapies for fungal pathogens |
| DE602006010979D1 (de) | 2005-01-19 | 2010-01-21 | Rigel Pharmaceuticals Inc | Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen |
| GB0504994D0 (en) | 2005-03-11 | 2005-04-20 | Biotica Tech Ltd | Novel compounds |
| US20060257337A1 (en) | 2005-04-28 | 2006-11-16 | David Sherris | Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis |
| EP1888550B1 (en) | 2005-05-12 | 2014-06-25 | AbbVie Bahamas Ltd. | Apoptosis promoters |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| BRPI0617162B8 (pt) | 2005-10-07 | 2021-05-25 | Exelixis Inc | compostos inibidores de fosfatidilinositol 3-quinase composições farmacêuticas que os contem e métodos de uso dos mesmos |
| CN101395155A (zh) | 2005-10-07 | 2009-03-25 | 埃克塞里艾克西斯公司 | PI3Kα的吡啶并嘧啶酮抑制剂 |
| CN103626742B (zh) | 2005-11-01 | 2017-04-26 | 塔格根公司 | 激酶的联-芳基间-嘧啶抑制剂 |
| EP2385053B1 (en) | 2005-11-17 | 2013-10-02 | OSI Pharmaceuticals, Inc. | Intermediates for the preparation of fused bicyclic mTOR inhibitors |
| EP2455382B1 (en) | 2005-12-13 | 2016-10-26 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| US20070203168A1 (en) | 2006-02-28 | 2007-08-30 | Zhao Jonathon Z | Isomers of rapamycin and 42-Epi-rapamycin, methods of making and using the same |
| TW200815429A (en) | 2006-04-11 | 2008-04-01 | Smithkline Beecham Corp | Thiazolidinedione derivatives as PI3 kinase inhibitors |
| MX2008013578A (es) | 2006-04-26 | 2009-03-23 | Hoffmann La Roche | Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k). |
| EP2074244A4 (en) | 2006-07-28 | 2011-11-23 | Pronomic Industry Ab | CRYSTAL BREEDING METHOD AND REACTOR CONCEPT |
| DK2074122T5 (da) | 2006-09-15 | 2014-03-17 | Pfizer Prod Inc | Pyrido (2, 3-d) pyrimidin0n-forbindelser og anvendelse deraf som pi3 inhibitorer |
| BRPI0622054B8 (pt) | 2006-09-22 | 2021-05-25 | Oxford Amherst Llc | composto e composição farmacêutica |
| WO2008070740A1 (en) | 2006-12-07 | 2008-06-12 | F.Hoffmann-La Roche Ag | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
| WO2008110491A2 (en) | 2007-03-09 | 2008-09-18 | University Of Basel | Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat |
| HRP20151386T1 (hr) | 2007-03-12 | 2016-02-26 | Ym Biosciences Australia Pty Ltd | Fenil aminopirimidinski spojevi i njihova primjena |
| WO2008118802A1 (en) | 2007-03-23 | 2008-10-02 | Regents Of The University Of Minnesota | Therapeutic compounds |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| US8158616B2 (en) | 2008-03-11 | 2012-04-17 | Incyte Corporation | Azetidine and cyclobutane derivatives as JAK inhibitors |
| US20090253733A1 (en) | 2008-04-02 | 2009-10-08 | Biointeractions, Ltd. | Rapamycin carbonate esters |
| AP2775A (en) | 2008-05-23 | 2013-09-30 | Wyeth Llc | Triazine compounds as P13 kinase and MTOR inhibitors |
| US8198441B2 (en) | 2008-06-20 | 2012-06-12 | Astrazeneca Ab | Process for the preparation of novel pyridopyrazines as mTOR kinase inhibitors |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| US8110578B2 (en) | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
| ES2345241B1 (es) | 2009-03-16 | 2011-09-08 | Lipopharma Therapeutics | Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos. |
| SG174527A1 (en) | 2009-03-27 | 2011-11-28 | Pathway Therapeutics Inc | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy |
| ES2500643T3 (es) | 2009-04-03 | 2014-09-30 | Verastem, Inc. | Compuestos de purina sustituidos con pirimidina como inhibidores de las cinasas |
| WO2010118208A1 (en) | 2009-04-09 | 2010-10-14 | Exelixis, Inc. | Benzoxazepin-4- (5h) -yl derivatives and their use to treat cancer |
| WO2011130232A1 (en) | 2010-04-13 | 2011-10-20 | Novartis Ag | Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor and an mtor inhibitor for treating cancer |
| CN103108873A (zh) | 2010-07-16 | 2013-05-15 | 皮拉马尔企业有限公司 | 作为激酶抑制剂的取代的咪唑并喹啉衍生物 |
| JO3003B1 (ar) | 2011-01-14 | 2016-09-05 | Lilly Co Eli | مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor |
| US8808256B2 (en) | 2012-01-16 | 2014-08-19 | Johnson & Johnson Vision Care, Inc. | Eye drug delivery system |
| US9072678B2 (en) | 2013-03-14 | 2015-07-07 | Pathak Holdings Llc | Methods for local drug delivery by microinjection |
| WO2015051043A1 (en) | 2013-10-01 | 2015-04-09 | Amgen Inc. | Biaryl acyl-sulfonamide compounds as sodium channel inhibitors |
| EP3102576B8 (en) | 2014-02-03 | 2019-06-19 | Vitae Pharmaceuticals, LLC | Dihydropyrrolopyridine inhibitors of ror-gamma |
| WO2016040806A1 (en) | 2014-09-11 | 2016-03-17 | The Regents Of The University Of California | mTORC1 INHIBITORS |
| US20160279108A1 (en) | 2015-02-24 | 2016-09-29 | University Of Kansas | Targeted mtor inhibitors |
| US10683308B2 (en) * | 2015-09-11 | 2020-06-16 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
| CA3061907A1 (en) | 2017-05-02 | 2018-11-08 | Revolution Medicines, Inc. | Rapamycin analogs as mtor inhibitors |
| AR112834A1 (es) | 2017-09-26 | 2019-12-18 | Novartis Ag | Derivados de rapamicina |
| IL314362A (en) | 2018-06-15 | 2024-09-01 | Janssen Pharmaceutica Nv | Rapamycin analogs and their uses |
| WO2020076738A2 (en) | 2018-10-12 | 2020-04-16 | Bellicum Pharmaceuticals, Inc | Protein-binding compounds |
| MX2021007247A (es) | 2018-12-18 | 2021-07-15 | Novartis Ag | Derivados de rapamicina. |
| EP3914245A4 (en) | 2019-01-22 | 2022-08-24 | Aeovian Pharmaceuticals, Inc. | MTORC-1 MODULATORS AND USES THEREOF |
| KR20210142689A (ko) | 2019-03-26 | 2021-11-25 | 노파르티스 아게 | 이소티아졸리딘 1,1-디옥시드 및 1,4-부탄 술톤 함유 라파마이신 유도체 및 이의 용도 |
| KR20220128345A (ko) * | 2019-12-05 | 2022-09-20 | 아나쿠리아 테라퓨틱스, 인코포레이티드 | 라파마이신 유사체 및 이의 용도 |
| WO2021195599A1 (en) | 2020-03-27 | 2021-09-30 | Aeovian Pharmaceuticals, Inc. | Mtorc1 modulators and uses thereof |
| EP4185590A2 (en) | 2020-07-21 | 2023-05-31 | Aeovian Pharmaceuticals, Inc. | Mtorc1 modulators and uses thereof |
-
2020
- 2020-12-04 KR KR1020227022865A patent/KR20220128345A/ko not_active Withdrawn
- 2020-12-04 AU AU2020397938A patent/AU2020397938A1/en active Pending
- 2020-12-04 MX MX2022006807A patent/MX2022006807A/es unknown
- 2020-12-04 IL IL293549A patent/IL293549A/en unknown
- 2020-12-04 CN CN202080095831.5A patent/CN115209897A/zh active Pending
- 2020-12-04 US US17/111,674 patent/US11819476B2/en active Active
- 2020-12-04 EP EP20895785.2A patent/EP4069223A4/en not_active Withdrawn
- 2020-12-04 CA CA3163680A patent/CA3163680A1/en active Pending
- 2020-12-04 TW TW109142952A patent/TW202134234A/zh unknown
- 2020-12-04 WO PCT/US2020/063351 patent/WO2021113665A1/en not_active Ceased
- 2020-12-04 JP JP2022534146A patent/JP2023506410A/ja active Pending
- 2020-12-04 BR BR112022010754A patent/BR112022010754A2/pt unknown
-
2023
- 2023-11-01 US US18/499,580 patent/US20240139164A1/en not_active Abandoned
- 2023-11-01 US US18/499,511 patent/US20240131012A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20240139164A1 (en) | 2024-05-02 |
| CN115209897A (zh) | 2022-10-18 |
| US11819476B2 (en) | 2023-11-21 |
| AU2020397938A1 (en) | 2022-06-23 |
| US20210186935A1 (en) | 2021-06-24 |
| KR20220128345A (ko) | 2022-09-20 |
| EP4069223A1 (en) | 2022-10-12 |
| EP4069223A4 (en) | 2023-12-20 |
| WO2021113665A1 (en) | 2021-06-10 |
| CA3163680A1 (en) | 2021-06-10 |
| US20240131012A1 (en) | 2024-04-25 |
| IL293549A (en) | 2022-08-01 |
| BR112022010754A2 (pt) | 2022-08-23 |
| TW202134234A (zh) | 2021-09-16 |
| JP2023506410A (ja) | 2023-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022006807A (es) | Análogos de rapamicina y usos de estos. | |
| PH12022551379A1 (en) | Substituted tetrahydrofurans as modulators of sodium channels | |
| MX2023012981A (es) | Compuestos para inhibir o degradar proteinas objetivo, composiciones que los comprenden, metodos para su preparacion y metodos para usarlos. | |
| MX2025003987A (es) | Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos | |
| MX2021000887A (es) | Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer. | |
| EP4438117A3 (en) | Tyk2 inhibitors and uses thereof | |
| PH12022550980A1 (en) | Small molecule degraders of helios and methods of use | |
| EP4613773A3 (en) | Irak degraders and uses thereof | |
| MX2020007797A (es) | Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos. | |
| PH12018502427A1 (en) | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders | |
| EP4374858A3 (en) | Benzimidazolone derived inhibitors of bcl6 | |
| PH12020552092A1 (en) | Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease | |
| EP4327809A3 (en) | Tyk2 inhibitors and uses thereof | |
| GEP20217242B (en) | Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors | |
| WO2014100071A3 (en) | Substituted pyrrolopyrimidines as hdm2 inhibitors | |
| GEP20247585B (en) | Furoindazole derivatives | |
| IL207976A0 (en) | Novel 02x7r antagonists and their use | |
| NZ736055A (en) | Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators | |
| EP4249071A3 (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| WO2019078968A3 (en) | Cyclic compounds as immunomodulating agents | |
| MX2023010711A (es) | Fenalquilaminas y métodos de preparación y uso de las mismas. | |
| PH12022550491A1 (en) | Perk inhibiting pyrrolopyrimidine compounds | |
| PH12022550843A1 (en) | Thienopyrimidones as trpa1 inhibitors | |
| PH12021552533A1 (en) | Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease | |
| MX2021007247A (es) | Derivados de rapamicina. |